Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01177 SINO BIOPHARM
RTNominal up2.770 +0.030 (+1.095%)
Others

06/07/2020 17:30

Sino Biopharm (01177) gets drug registration approval

[ET Net News Agency, 6 July 2020] Sino Biopharmaceutical Limited (01177) said "Invert
Sugar Injection" (brand name: Fenghaixin), a body fluid and energy supplement developed by
the group, has obtained approval for drug registration granted by the National Medical
Products Administration of the People's Republic of China.
The product is available in 5% (250ml: glucose 6.25g and fructose 6.25g) and 10% (250ml:
glucose 12.5g and fructose 12.5g) specifications. It can be directly infused clinically to
replenish body fluid and energy, especially with patients with diabetes and patients with
insulin resistance such as burn trauma and postoperative, and can also be used for the
treatment of drug poisoning and alcoholism. (RC)

Back to Others

Remark: Real time quote last updated: 26/04/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.